The pharmacological management of violence in schizophrenia: a structured review

References

• Fazel S, Grann M. The population impact of severe mental illness on violent crime. Am. J. Psychiatry163(8), 1397–1403 (2006).
   PubMed Web of Science ®Google Scholar
• Milton J, Amin S, Singh S et al. Aggressive incidents in first-episode psychosis. Br. J. Psychiatry178, 433–440 (2001).
   PubMed Web of Science ®Google Scholar
• Fazel S, Gulati G, Linsell L, Geddes J, Grann M. Schizophrenia and violence: systematic review and meta-analysis. PLoS Med.6(8), e1000120 (2009).
   PubMed Web of Science ®Google Scholar
• Shaw J, Hunt I, Flynn S et al. Rates of mental disorder in people convicted of homicide. National clinical survey. Br. J. Psychiatry188, 143–147 (2006).
   PubMed Web of Science ®Google Scholar
• Gottlieb P, Gabrielsen G, Kramp P. Psychotic homicides in Copenhagen from 1959 to 1983. Acta Psychiatr. Scand.76(3), 285–292 (1987).
   PubMed Web of Science ®Google Scholar
• Fazel S, Grann M. Psychiatric morbidity among homicide offenders: a Swedish population study. Am. J. Psychiatry161(11), 2129–2131 (2004).
   PubMed Web of Science ®Google Scholar
• Arango C, Calcedo Barba A, González-Salvador T, Calcedo Ordóñez A. Violence in inpatients with schizophrenia: a prospective study. Schizophr. Bull.25(3), 493–503 (1999).
   PubMed Web of Science ®Google Scholar
• Barlow K, Grenyer B, Ilkiw-Lavalle O. Prevalence and precipitants of aggression in psychiatric inpatient units. Austr. NZ J. Psychiatry34(6), 967–974 (2002).
   Google Scholar
• Humphreys M, Johnstone M, MacMillan J, Taylor P. Dangerous behaviour preceding first admissions for schizophrenia. Br. J. Psychiatry161, 501–505 (1992).
   PubMed Web of Science ®Google Scholar
• Soyka M, Morhart-Klute V, Schoech H. Delinquency and criminal offenses in former schizophrenic inpatients 7–12 years following discharge. Eur. Arch. Psychiatry Clin. Neurosci.254(5), 289–294 (2004).
   PubMed Web of Science ®Google Scholar
• Appelbaum P, Robbins P, Monahan J. Violence and delusions: data from the MacArthur violence risk assessment study. Am. J. Psychiatry157, 566–572 (2000).
   PubMed Web of Science ®Google Scholar
• Wallace C, Mullen P, Burgess P. Criminal offending in schizophrenia over a 25-year period marked by deinstitutionalization and increasing prevalence of comorbid substance use disorders. Am. J. Psychiatry161(4), 716–727 (2004).
   PubMed Web of Science ®Google Scholar
• Fazel S, Långström N, Hjern A, Grann M, Lichtenstein P. Schizophrenia, substance abuse, and violent crime. JAMA301(19), 2016–2023 (2009).
   PubMed Web of Science ®Google Scholar
• Swartz M, Swanson J, Hiday V, Borum R, Wagner H, Burns B. Violence and severe mental illness: the effects of substance abuse and nonadherence to medication. Am. J. Psychiatry155(2), 226–231 (1998).
   PubMed Web of Science ®Google Scholar
• Nolan K, Volavka J, Mohr P, Czobor P. Psychopathy and violent behavior among patients with schizophrenia or schizoaffective disorder. Psychiatr. Serv.50, 787–792 (1999).
   PubMed Web of Science ®Google Scholar
• Tengström A, Hodgins S, Grann M, Långström N, Kullgren G. The role of psychopathy and substance use disorders: schizophrenia and criminal offending. Crim. Justice Behav.31(4), 367–391 (2004).
   Web of Science ®Google Scholar
• NICE guidelines: Antisocial personality disorder: treatment, management and prevention. NICE clinical guideline 77. National Institute of Health and Clinical Excellence, London, UK (2009).
   Google Scholar
• Duggan C, Huband N, Smailagic N, Ferriter M, Adams C. The use of psychological treatments for people with personality disorder: a systematic review of randomized controlled trials. Pers. Ment. Health1(2), 95–125 (2007).
   Web of Science ®Google Scholar
• Duggan C, Huband N, Smailagic N, Ferriter M, Adams C. The use of pharmacological treatments for people with personality disorder: a systematic review of randomized controlled trials. Pers. Ment. Health2(3), 119–170 (2008).
   Web of Science ®Google Scholar
• Citrome L, Volavka J. Management of violence in schizophrenia. Psychiatr. Ann.30(1), 41–52 (2000).
   Google Scholar
• Volavka J, Citrome L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int. J. Clin. Pract.62(8), 1237–1245 (2008).
   PubMed Web of Science ®Google Scholar
• Citrome L, Volavka J, Czobor P et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr. Serv.52, 1510–1514 (2001).
   PubMed Web of Science ®Google Scholar
• Krakowski M, Czobor P, Citrome L, Bark N, Cooper T. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry63(6), 622–629 (2006).
   PubMed Web of Science ®Google Scholar
• Aleman A, Kahn R. Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials. Eur. Neuropsychopharmacol.11(4), 289–293 (2001).
   PubMed Web of Science ®Google Scholar
• Hosák L Libiger J. Antiepileptic drugs in schizophrenia: a review. Eur. Psychiatry17(7), 371–378 (2002).
   PubMed Web of Science ®Google Scholar
• Dose M, Hellweg R, Yassouridis A, Theison M, Emrich M. Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry31(4), 122–112 (1998).
   PubMed Web of Science ®Google Scholar
• De Vogelaer J. Carbamazepine in the treatment of psychotic and behavioral disorders. A pilot study. J. Psych. Neuros. Acta Psychiatr. Belg.81(6), 532–541 (1981).
   PubMedGoogle Scholar
• Atkins D, Briss P, Eccles M et al. Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system. BMC Health Serv. Res.5, 25 (2005).
   PubMedGoogle Scholar
• Guyat G, Oxman A, Vist G et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ336, 924–926 (2008).
   PubMedGoogle Scholar
• Ascher-Svanum H, Faries D, Zhu B et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J. Clin. Psychiatry76, 453–460 (2006).
   Google Scholar
• Alia-Klein N, O’Rourke T, Goldstein R et al. Insight into illness and adherence to psychotropic medications are separately associated with violence severity in a forensic sample. Aggress. Behav.33, 86–96 (2007).
   PubMed Web of Science ®Google Scholar
• Lindenmayer J, Liu-Seifert H, Kulkarni P et al. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J. Clin. Psychiatry70(7), 990–996 (2009).
   PubMed Web of Science ®Google Scholar
• Arango C, Bombín I, González-Salvador T, García-Cabeza I, Bobes J. Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. Eur. Psychiatry21(1), 34–40 (2005).
   PubMedGoogle Scholar
• Hennen J, Baldessarini R. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr. Res.73(2), 139–145 (2005).
   PubMed Web of Science ®Google Scholar
• Volavka J, Czobor P, Nolan K et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J. Clin. Psychopharmacol.24(2), 225–228 (2004).
   PubMed Web of Science ®Google Scholar
• Swanson J, Swartz M, Van Dorn R et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br. J. Psychiatry193(1), 37–43 (2008).
   PubMed Web of Science ®Google Scholar
• Volavka J, Zito J, Vitrai J et al. Clozapine effects on hostility and aggression in schizophrenia. J. Clin. Psychiatry13, 287–289 (1993).
   Google Scholar
• Swanson J, Swartz M, Elbogen E. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophr. Bull.30(1), 3–20 (2004).
   PubMed Web of Science ®Google Scholar
• Bitter I, Czobor P, Dossenbach M, Volavka J. Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO). Eur. Psychiatry20(5–6), 403–408 (2005).
   PubMedGoogle Scholar
• Arango C, Bernardo M. The effect of quetiapine on aggression and hostility in patients with schizophrenia. Hum. Psychopharmacol.20(4), 237–241 (2005).
   PubMed Web of Science ®Google Scholar
• Citrome L, Volavka J, Czobor P, Brook S, Loebel A, Mandel F. Efficacy of ziprasidone against hostility in schizophrenia: post hoc analysis of randomized, open-label study data. J. Clin. Psychiatry67(4), 638–642 (2006).
   PubMedGoogle Scholar
• Cade J. Lithium salts in the treatment of psychotic excitement. Med. J. Aust.2(10), 349–352 (1949).
   PubMed Web of Science ®Google Scholar
• Van Putten T, Sanders D. Lithium in treatment failures. J. Nerv. Ment. Dis.161(4), 255–264 (1975).
   PubMedGoogle Scholar
• Prado-Lima P, Knijnik L, Juruena M, Padilla A. Lithium reduces maternal child abuse behaviour: a preliminary report. J. Clin. Pharm. Ther.26(4), 279–282 (2001).
   PubMedGoogle Scholar
• Shear M. Effect of lithium on human aggression. Nature230(12), 113–114 (1971).
   PubMedGoogle Scholar
• Sheard M, Marini J, Bridges C, Wagner E. The effect of lithium on impulsive aggressive behavior in man. Am. J. Psychiatry133, 1409–1413 (1976).
   PubMed Web of Science ®Google Scholar
• Tupin J, Smith D, Clanon T, Kim L, Nugent A, Group A. The long-term use of lithium in aggressive prisoners. Compr. Psychiatry14(4), 311–317 (1973).
   PubMed Web of Science ®Google Scholar
• Dorrego M, Canevaro L, Kuzis G, Sabe L, Starkstein A. A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder. J. Neuropsychiatry Clin. Neurosci.14, 289–295 (2002).
   PubMed Web of Science ®Google Scholar
• Lawson W, Nanos J. Effects of divalproex on behaviour of jail inmates. Prog. Neuropsychopharmacol.32(3), 209–210 (2008).
   Google Scholar
• Huband N, Ferriter M, Nathan R, Jones H. Antiepileptics for aggression and associated impulsivity. Cochrane Database Syst. Rev.(2), CD003499 (2010).
   Google Scholar
• Citrome L, Casey D, Daniel D, Wozniak P, Kochan L, Tracy K. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatr. Serv.55, 290–294 (2004).
   PubMed Web of Science ®Google Scholar
• Kelly D, Conley R, Feldman S, Yu Y, McMahon R, Richardson C. Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. Psychiatr. Q.77(1), 81–95 (2006).
   PubMed Web of Science ®Google Scholar
• Citrome L, Shope C, Nolan K, Czobor K, Volavka J. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. Int. Clin. Psychopharmacol.22(6), 356–362 (2007).
   PubMedGoogle Scholar
• Gobbi G, Gaudreau P, Leblanc N. Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. J. Clin. Psychopharmacol.26(5), 467–473 (2006).
   PubMed Web of Science ®Google Scholar
• Carney S, Cowen P, Geddes J et al. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet361(9360), 799–780 (2003).
   PubMedGoogle Scholar
• Tharyan P, Adams C. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst. Rev.(2), CD000076 (2005).
   Google Scholar
• Swanson J, Swartz M, Van Dorn R et al. A national study of violent behavior in persons with schizophrenia. Arch. Gen. Psychiatry63, 490–499 (2006).
   PubMed Web of Science ®Google Scholar
• Smith K, Surphilis W, Gynther M, Shimkunas A. ECT–chlorpromazine and chlorpromazine compared in the treatment of schizophrenia. J. Nerv. Ment. Dis.144, 284–290 (1967).
   Web of Science ®Google Scholar
• Hirose S, Ashby C, Mills M. Effectiveness of ECT combined with risperidone against aggression in schizophrenia. J. ECT17(1), 22–26 (2001).
   PubMedGoogle Scholar
• Maoz G, Stein D, Meged S et al. The antiaggressive action of combined haloperidol–propranolol treatment in schizophrenia. Eur. Psychol.5(4), 312–325 (2000).
   Google Scholar
• Alpert M, Allan E, Citrome L et al. A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients. Psychopharmacol. Bull.26(3), 367–371 (1990).
   PubMedGoogle Scholar
• Allan E, Alpert M, Sison C et al. Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients. J. Clin. Psychiatry57, 455–459 (1996).
   PubMedGoogle Scholar
• Ratey J, Sorgi P, O’Driscoll G et al. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study. J. Clin. Psychiatry53, 41–46 (1992).
   PubMed Web of Science ®Google Scholar
• Cantwell R, Brewin J, Glazebrook C et al. Prevalence of substance misuse in first-episode psychosis. Br. J. Psychiatry174, 150–153 (1999).
   PubMed Web of Science ®Google Scholar
• Duke P. Comorbid non-alcohol substance misuse among people with schizophrenia. Epidemiological study in central London. Br. J. Psychiatry179, 509–513 (2001).
   PubMed Web of Science ®Google Scholar
• Fazel S, Grann M, Carlström E, Lichtenstein P, Långström N. Risk factors for violent crime in schizophrenia: a national cohort study of 13,806 patients. J. Clin. Psychiatry70(3), 362–369 (2009).
   PubMed Web of Science ®Google Scholar
• Volavka J, Swanson J. Violent behaviour in mental illness: the role of substance abuse. JAMA304, 3–4 (2010).
   Google Scholar
• Wobrock T. Soyka M. Pharmacotherapy of schizophrenia with comorbid substance use disorder – reviewing the evidence and clinical recommendations. Prog. Neuropsychopharmacol. Biol. Psychiatry32(6), 1375–1385 (2006).
   Google Scholar
• Green A, Noordsy D, Brunette M, O’Keefe C. Substance abuse and schizophrenia: pharmacotherapeutic intervention. J. Subst. Abuse Treat.34(1), 61–71 (2008).
   PubMed Web of Science ®Google Scholar
• Brown E, Nejtek V, Perantie D et al. Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation. J. Clin. Psychopharmacol.23(4), 384–388 (2003).
   PubMed Web of Science ®Google Scholar
• Berk M, Brook S, Trandafir A. A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. Int. Clin. Psychopharmacol.14(3), 177–180 (1999).
   PubMed Web of Science ®Google Scholar
• Smelson D, Ziedonis D, Williams J et al. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J. Clin. Psychopharmacol.26(1), 9–12 (2006).
   PubMed Web of Science ®Google Scholar
• Sayers S, Campbell E, Kondrich J et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J. Nerv. Ment. Dis.193(6), 379–386 (2005).
   PubMed Web of Science ®Google Scholar
• Green A, Tohen M, Hamer R et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr. Res.66(2–3), 125–135 (2004).
   PubMed Web of Science ®Google Scholar
• Akerele E, Levin F. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. Am. J. Addict.16(4), 260–268 (2007).
   PubMed Web of Science ®Google Scholar
• Rubio G, Martinez I, Ponce G et al. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can. J. Psychiatry51(8), 531–539 (2006).
   PubMed Web of Science ®Google Scholar
• Petrakis I, O’Malley S, Rounsaville B et al. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology172(3), 291–297 (2004).
   PubMed Web of Science ®Google Scholar
• Kalyoncu A, Mirsal H, Pektas O et al. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? J. Psychopharmacol.19(3), 301–305 (2005).
   PubMed Web of Science ®Google Scholar
• Chambers J, Yiend J, Barrett B et al. Outcome measures used in forensic mental health research: a structured review. Crim. Behav. Ment. Health19(1), 9–27 (2009).
   PubMed Web of Science ®Google Scholar
• Volavka J, Citrome L. Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. Schizophr. Res.35, S23–S33 (1999).
   PubMedGoogle Scholar
• Jones P, Barnes T, Davies L et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch. Gen. Psychiatry63, 1079–1087 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenheck R, Leslie D, Sindelar J et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am. J. Psychiatry163, 2080–2089 (2006).
   PubMed Web of Science ®Google Scholar
• Haw C, Stubbs J. A survey of the off-label use of mood stabilizers in a large psychiatric hospital. J. Psychopharmacol.19(4), 402–407 (2005).
   PubMedGoogle Scholar